Last updated: February 16, 2026
What is NDC 42192-0152?
NDC 42192-0152 corresponds to Genentech’s Venclexta (venetoclax), approved by the FDA in April 2016. It is indicated for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and acute myeloid leukemia (AML) in combination with other therapies. Venclexta acts as a BCL-2 inhibitor, promoting apoptosis in cancer cells.
How is the current market landscape structured?
1. Market Size and Growth
The global hematologic malignancy therapeutics market, including CLL and AML, was valued at approximately $7.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8% over the next five years, reaching roughly $11.2 billion by 2027 [1].
Within this market, venetoclax holds a significant share due to its approval for multiple indications and favorable efficacy profile. The U.S. accounted for over 45% of sales in 2022 owing to high adoption and reimbursement coverage.
2. Key Competitors
- AbbVie’s Venclexta (venetoclax): Primary branded therapy, dominant in the CLL space.
- Novartis’ Tab-cel: Approved for specific AML indications.
- Generic alternatives: Not yet available; patent expiry is anticipated around 2029.
3. Pricing and Reimbursement Landscape
- U.S.: Average wholesale price (AWP) for Venclexta: $16,000–$18,000 per month per patient.
- Commercial insurers typically reimburse at 70–85% of AWP, leaving patient copays around $3,000–$4,000 per month.
- Medicare Part D covers most costs, though negotiated prices and discounts apply.
Pricing varies based on indication, treatment duration, and discounts negotiated by pharmacy benefit managers (PBMs).
What are the projected price trends?
1. Short-Term (Next 1-2 Years)
Price reductions are unlikely unless patent challenges or biosimilar development materialize. Current trends suggest slight decreases through rebates and formulary negotiations. The drug remains premium-priced at approximately $16,000 per month.
2. Mid to Long-Term (3-5 Years)
- Patent expiration: Predicted around 2029, opening the door for biosimilar competition.
- Biosimilar development: Limited, as biosimilars have a different approval pathway than generics but could reduce prices by 30-50% once approved.
- Pricing pressure: Expected to grow, driven by payer negotiations, competitive therapies, and potential biosimilar entry.
Estimated price decline: 10–25% over five years post-patent expiry, largely driven by biosimilar market penetration.
3. Effect of Market Dynamics
- The introduction of combination therapies may influence monotherapy pricing.
- Increased adoption in AML and expanded indications may support price stability, counteracting downward pressure.
What are the future market opportunities and challenges?
Opportunities:
- Expansion of indications, including earlier lines of therapy.
- Development of combination regimens with other targeted agents.
- Genomic testing integration to personalize treatment, possibly increasing demand.
Challenges:
- Patent cliff approaching 2029.
- Competition from emerging therapies (e.g., BTK inhibitors).
- Price sensitivity in healthcare systems.
Summary Table: Price Projections for NDC 42192-0152 (Venclexta)
| Year |
Price Range (Monthly) |
Key Drivers |
Notes |
| 2023 |
~$16,000–$18,000 |
Market stability, no biosimilars available |
Slight discounts via rebates and negotiations |
| 2025 |
~$15,000–$17,000 |
Competitive pressures, ongoing negotiations |
Potential for increased biosimilar activity |
| 2027 |
~$14,000–$16,000 |
Approaching patent expiry, biosimilar developments |
Market response to biosimilar entry possible |
| 2029 |
~$8,000–$12,000 |
Patent expiry, biosimilar market entry |
Significant price reduction expected |
| 2030+ |
~$8,000 or lower |
Biosimilar saturation |
Price stabilization in generics/biosimilars market |
Key Takeaways
- NDC 42192-0152 (Venclexta) remains a high-priced, rapidly growing oncologic therapy.
- Current price points are around $16,000/month, with limited short-term declines.
- Patent expiry in 2029 may lead to substantial price reductions due to biosimilar competition.
- Market expansion strategies, ongoing indications, and biosimilar developments significantly influence future pricing.
- Competitive landscape and healthcare policies are critical considerations in shaping the market.
5 FAQs
1. When will biosimilars for Venclexta likely enter the market?
Potential biosimilar approval is expected around 2029, post-patent expiry, contingent on regulatory pathways and development progress.
2. How much could prices decrease with biosimilar entry?
Biosimilar competition could reduce prices by 30–50%, translating to monthly costs of approximately $8,000–$12,000.
3. What factors could accelerate price declines?
Regulatory approval of biosimilars, increased market penetration, and payer negotiations can hasten reductions.
4. Are there any existing alternatives to Venclexta?
Therapies like ibrutinib (Imbruvica) and idelalisib target similar indications but differ in mechanism and approval status.
5. How do indications impact pricing?
Expanded indications increase demand, potentially maintaining or increasing prices unless competition arises.
Sources:
[1] Global Hematologic Malignancies Market Forecast, 2022.
[2] FDA approvals and label information.
[3] IQVIA. Pharmaceutical market and pricing data.
